




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



On the plausibility of late neuropsychiatric manifestations associated with the COVID-19 pandemic



Dear Sir

Recognition of the association between acute and subacute different *neuropsychiatric manifestations* with the infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic, is progressively being recognized [1]. *The potential emergence of late onset neuropsychiatric manifestations after infection with SARS-CoV-2* remains to be discussed. After the “Spanish” influenza pandemic in the 20th century, an outbreak of encephalitis lethargica (EL) [2], a neuropsychiatric disorder of possible autoimmune origin emerged occurring soon after the acute phase or at some time later [3]. It's worthwhile to highlight that manifestations of EL such as sleep disturbance, fatigue, psychosis, catatonia, movement disorders among others were identified in previous historical epidemics since the 15th century [3]. Molecular mimicry leading to damage of the brainstem respiratory pace-maker [4] and occurrence of neurological autoimmune disorders after SARS-CoV-2 infection (Gilliam Barré syndrome and its variants) [5,6] are indicative of the potential inducer of autoimmunity involving the nervous system on the long-term.

Apart from a single study showing an association of seropositivity for specific coronavirus (HCoV-NL63) with chronic mood disorder [7], nothing is known about the possibility of late *neuropsychiatric manifestations associated with coronavirus infections*.

The is indirect evidence (Fig. 1) supporting the biological pathophysiology of late occurrence of *neuropsychiatric manifestations after SARS-CoV-2 infection*.

Proinflammatory cytokines such as the interleukin-6 (IL-6) [8] or tumour necrosis factor alpha ($TNF-\alpha$)⁹ are associated with development of late *onset neuropsychiatric manifestations*. COVID-19 is associated with

systemic inflammatory storm with a massive release of cytokines, chemokines, including IL-6 and $TNF-\alpha$ ¹⁰. Delirium it's not rare in patients with COVID-19 [1], suggesting that at least acutely, significant break of blood brain barrier and neuroinflammation occurs. Latent viral chronic brain infection caused by viruses, per example the human herpes virus 6 infections or the measles virus are associated with late cognitive and behaviour disturbances [9,10]. In murine models, coronaviruses can invade the brain and cause chronic infection [11,12]. The presence of coronavirus was demonstrated in the brain tissue in a single patient after SARS-CoV infection [13]. Very low levels of SARS-CoV-2 was detected in very few patients who died from COVID-19 [14]. Despite the inexistence of documented cases of 2019-nCoV chronic brain infection, the invasiveness and neurotropism of the virus [15], obliges to leave this possibility open.

SARS-CoV-2 is worldwide distributed and affecting people with different genetic background. The virus itself, is also genetically adapting to humans [16]. Hence, in the context of an infinitude of virus-host interactions, the possibility of *late neuropsychiatric manifestations after SARS-CoV-2 infection* should be considered. Careful monitoring of chronic or *late neuropsychiatric manifestations is important to uncover mechanisms of the disease and guide interventions to prevent. Most patients with SARS-CoV-2 infection are asymptomatic and the durability of serological markers of infection is unknow. This might preclude studies based on serological status. Due to the large variability of SARS-CoV-2 infection prevalence between sites, ecological studies might be a promising design to address patterns of occurrence of late neuropsychiatric manifestations.*




Fig. 1. Schematic representation of potential mechanisms involved in the occurrence of late neuropsychiatric complications.

References

- [1] A.A. Asadi-pooya, L. Simani, Journal of the neurological sciences central nervous system manifestations of COVID-19 : a systematic review, *J. Neurol. Sci.* 413 (April) (2020) 116832, <https://doi.org/10.1016/j.jns.2020.116832>.
- [2] Economo C von, Encephalitis Lethargica. Its Sequelae and treatment, *Arch. Neurol. Psychiatr.* 28 (5) (1932) 1242, <https://doi.org/10.1001/archneurpsyc.1932.02240050278031>.
- [3] L.A. Hoffman, J.A. Vilensky, Encephalitis lethargica : 100 years after the epidemic history of encephalitis lethargica, *Brain.* 6 (2017) 1–6, <https://doi.org/10.1093/brain/awx177>.
- [4] F. Angileri, S. Legare, A.M. Gammazza, Macario E.C. De, A.J.L. Macario, F. Cappello, Molecular mimicry may explain multi-organ damage in COVID-19, *Autoimmun. Rev.* 10 (2020) 2591, <https://doi.org/10.1016/j.autrev.2020.102591>.
- [5] A.S. Zubair, L.S. McAlpine, T. Gardin, S. Farhadian, D.E. Kuruvilla, S. Spudich, Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review, *JAMA Neurol.* (2020) 1–10, <https://doi.org/10.1001/jamaneurol.2020.2065>.
- [6] Z. Sedaghat, N. Karimi, Guillain Barre syndrome associated with COVID-19 infection: a case report, *J. Clin. Neurosci.* 76 (January) (2020) 233–235.
- [7] O. Okusaga, R.H. Yolken, P. Langenberg, et al., Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts, *J. Affect. Disord.* 130 (1–2) (2011) 220–225, <https://doi.org/10.1016/j.jad.2010.09.029>.
- [8] A. Johansson, T. Olsson, B. Carlberg, M.F. K Karlsson, Hypercortisolism after stroke—partly Cytokine- mediated ? *J. Neurol. Sci.* 20 (1997) 43–47, [https://doi.org/10.1016/s0022-510x\(96\)05308-7](https://doi.org/10.1016/s0022-510x(96)05308-7).
- [9] B. Reddy, S. Das, S. Guruprasad, Primary psychiatric manifestations of subacute Sclerosing Panencephalitis: a case report and the literature review, *Psychosomatics.* 59 (4) (2017) 408–4012, <https://doi.org/10.1016/j.psym.2017.12.004>.
- [10] B.K. Prusty, N. Gulve, S. Govind, et al., Active HHV-6 infection of cerebellar Purkinje cells in mood disorders, *Front. Microbiol.* 9 (2018) 1–12, <https://doi.org/10.3389/fmicb.2018.01955> (August).
- [11] S. Kyuwa, K. Yamaguchi, Y. Toyoda, K. Fujiwara, J. Hilgers, Acute and late disease induced by murine coronavirus, strain JHM, in a series of recombinant inbred strains between BALB/cHeA and STS/A mice, *Microb. Pathog.* 12 (2) (1992) 95–104, [https://doi.org/10.1016/0882-4010\(92\)90112-2](https://doi.org/10.1016/0882-4010(92)90112-2).
- [12] C. Adami, J. Pooley, J. Glomb, et al., Evolution of mouse hepatitis virus (MHV) during chronic infection: Quasispecies nature of the persisting MHV RNA, *Virology.* 209 (2) (1995) 337–346, <https://doi.org/10.1006/viro.1995.1265>.
- [13] J. Xu, S. Zhong, J. Liu, et al., Detection of severe acute respiratory syndrome coronavirus in the brain : potential role of the chemokine Mig in pathogenesis, *Clin. Infect. Dis.* 41 (2005) 1089–96, 2005;41(6):1089-1096.
- [14] Isaac H. Solomon, Erica Normandin, Shamik Bhattacharyya, Shibani S. Mukerji, Kiana Keller, Ahya S. Ali, Gordon Adams, L. Jason, Hornick 1, Robert F Padera Jr PS. Neuropathological features of Covid-19, *N. Engl. J. Med.* 12 (2020) 32530583, <https://doi.org/10.1056/NEJMc2019373>.

- [15] G.C. Cardona, L.D.Q. Pájaro, I.D.Q. Marzola, Y.R. Villegas, L.R.M. Salazar, *Journal of the Neurological Sciences*, 412 (2020) 116824, , <https://doi.org/10.1016/j.jns.2020.116824>.
- [16] T. Phan, Genetic diversity and evolution of SARS-CoV-2, *Infect. Genet. Evol.* 81 (February) (2020) 104260, , <https://doi.org/10.1016/j.meegid.2020.104260>.

Ana André^a, Catarina Félix^a, Mafalda Corvacho^b, Hipólito Nzwalo^{c,*}
^a *Neurology Department, Algarve University Hospital, Portugal*
^b *Psychiatry Department, Algarve University Hospital, Portugal*
^c *Faculty of Medicine and Biomedical Medicine, University of Algarve, Portugal*
E-mail address: hjnzwalo@ualg.pt (H. Nzwalo).

* **Corresponding author** at: Faculty of Medicine and Biomedical Sciences, University of Algarve, Campus da Penha, Faro 8005-139, Portugal.